Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.
Boston Scientific, an MD+DI Medtech Company of the Year finalist, announced positive three-year primary endpoint results over the weekend from the OPTION global clinical trial of its Watchman Flx left ...
(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...
On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results